These authors contributed equally to this work.
Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity
Article first published online: 14 APR 2011
© 2011 Japanese Cancer Association
Volume 102, Issue 6, pages 1164–1170, June 2011
How to Cite
Moriwaki, K., Okudo, K., Haraguchi, N., Takeishi, S., Sawaki, H., Narimatsu, H., Tanemura, M., Ishii, H., Mori, M. and Miyoshi, E. (2011), Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity. Cancer Science, 102: 1164–1170. doi: 10.1111/j.1349-7006.2011.01923.x
- Issue published online: 20 MAY 2011
- Article first published online: 14 APR 2011
- Accepted manuscript online: 10 MAR 2011 11:17AM EST
- (Received November 15, 2010/Revised February 21, 2011/Accepted February 28, 2011/Accepted manuscript online March 10, 2011)
Fig. S1. Differential glycan profiling of CD133+CD13− and CD133+CD13+ cells isolated from Hep3B cells using a lectin microarray.
Fig. S2. Focused differential glycan profiling of CD133+CD13− and CD133+CD13+ cells isolated from Hep3B cells.
Table S1. Differential expression profiling of 186 glycogenes between CD133+CD13− and CD133+CD13+ cells.
Table S2. The tumor-initiating ability of CD133+CD13−SSA− and CD133+CD13−SSA+ cells among Hep3B cells.
|CAS_1923_sm_FigS1.TIF||194K||Supporting info item|
|CAS_1923_sm_FigS2.TIF||90K||Supporting info item|
|CAS_1923_sm_TablesS1-S2.doc||126K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.